Hepatitis C pharmacogenetics: State of the art in 2010

Nezam H. Afdhal, John G. McHutchison, Stefan Zeuzem, Alessandra Mangia, Jean Michel Pawlotsky, Jeffrey S. Murray, Kevin V. Shianna, Yasuhito Tanaka, David L. Thomas, David R. Booth, David B. Goldstein

Research output: Contribution to journalArticle

Abstract

In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.

Original languageEnglish
Pages (from-to)336-345
Number of pages10
JournalHepatology
Volume53
Issue number1
DOIs
Publication statusPublished - Jan 2011

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Hepatitis C pharmacogenetics: State of the art in 2010'. Together they form a unique fingerprint.

  • Cite this

    Afdhal, N. H., McHutchison, J. G., Zeuzem, S., Mangia, A., Pawlotsky, J. M., Murray, J. S., Shianna, K. V., Tanaka, Y., Thomas, D. L., Booth, D. R., & Goldstein, D. B. (2011). Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology, 53(1), 336-345. https://doi.org/10.1002/hep.24052